Thymosin Alpha-1 (Tα1) and Thymalin are both catalogued as "thymic peptides" and both are marketed to researchers with the same immune-modulation framing. They are not the same class of product, and the evidence behind them was generated in very different ways. Both carry a Moderate grade in the Peptide Data compound library — but the grade is earned differently in each case, and comparing them is a useful illustration of how the four-tier system works: it grades the quality and directness of the human evidence, not how promising or how popular a compound is.

1. "Thymic peptide" is a family label, not a chemical class

The thymus is the organ in which T lymphocytes mature, and it produces a group of peptides that regulate that process. At least three distinct entities sit under the thymic-peptide heading:

  • Thymosin Alpha-1 (Tα1) — a synthetic 28-amino-acid peptide, the best characterised of the group [1,2].
  • Thymulin — a zinc-dependent nonapeptide.
  • Thymalin — a polypeptide preparation isolated from calf thymus, whose short-peptide constituents include the dipeptide EW (later synthesised separately as thymogen), the dipeptide KE (vilon) and the tripeptide EDP (crystagen) [11].

They share a tissue of origin, not a structure or a pharmacology. Grouping them by "thymus" is a catalogue convenience; the evidence has to be read compound by compound.

2. Thymosin Alpha-1: a synthetic peptide with a randomised clinical literature

Tα1 was isolated and characterised in the 1970s [1] and has been developed commercially as an immunomodulator (thymalfasin, marketed in some countries as Zadaxin). Its described mechanisms include promoting T-cell maturation, enhancing dendritic-cell maturation and antigen presentation, shifting cytokine balance toward a Th1 profile (IL-2, interferon-γ), acting as an endogenous ligand at TLR2 and TLR9, and stimulating NK-cell cytotoxicity [2,10].

What makes Tα1 unusual among compounds sold as research peptides is that its literature includes randomised controlled trials and meta-analyses rather than case reports:

  • Chronic hepatitis B and C. Multiple RCTs and meta-analyses report improved virological and immunological response, largely in Asian cohorts [3,4]. This was the indication on which the compound was originally licensed outside the UK; the arrival of direct-acting antivirals has since displaced it from that role.
  • Sepsis. The evidence here is genuinely mixed. The ETASS trial (n=361 severe sepsis patients) reported a 28-day mortality difference that reached statistical significance only on log-rank analysis [5]. Subsequent systematic reviews and meta-analyses suggested a possible mortality benefit, but with high between-study heterogeneity and a sample that did not reach the required information size [7,8,9]. The 2025 TESTS trial — a large, multicentre, placebo-controlled RCT (n=1,106) — found no clear reduction in 28-day all-cause mortality in the overall sepsis population, with pre-specified subgroup signals in older patients and those with diabetes that require prospective confirmation [6].

Read against our grading rules, the hepatitis indication sits above the sepsis indication: for sepsis the human evidence is best described as Limited, while the compound-level grade of Moderate reflects the existence of randomised human evidence across its programme, not a uniform verdict for every indication.

3. Thymalin: a deep but geographically narrow clinical record

Thymalin is a polypeptide complex extracted from calf thymus, developed within the Soviet-era peptide-bioregulator programme and registered as a medicine in the Russian Federation [11,12]. Its reported effects centre on restoring T-lymphocyte populations and normalising cytokine and coagulation markers in immune-suppressed or older patients, and it has been used clinically in Russia and parts of Eastern Europe for viral and bacterial infections, post-surgical immune deficit, and recovery after chemotherapy or radiotherapy [11].

The record is real human clinical experience, and it is extensive. Its limitations are equally real:

  • The great majority of studies were published in Russian-language journals and have not been independently replicated in Western trials.
  • Many are small, unblinded, or lack placebo controls meeting modern standards.
  • The preparation is a complex extract rather than a single defined sequence, which makes batch-to-batch comparison harder than for a synthetic peptide.
  • The most recent accessible human data — a single-centre observational comparison in older patients with severe COVID-19 (36 treated vs 44 controls) — is hypothesis-generating, not confirmatory [12].

Thymalin is therefore graded Moderate as well, but for a different reason: not because modern randomised evidence exists, but because there is substantial human clinical use underpinned by a coherent (if debated) mechanistic rationale [11].

4. The same grade, two different ceilings

Both compounds land on Moderate, and this is exactly where a grade can mislead if it is read as a score.

  • Tα1's grade is set by the design quality of its evidence: randomised trials exist, including one large trial with a null primary endpoint. That null result does not erase the grade, but it does cap the confidence that can be placed in the sepsis indication.
  • Thymalin's grade is set by the absence of that design quality. Its volume of human use is greater than Tα1's in some indications, but volume is not the same as certainty.

A grade is not a safety verdict, not a legal status, and not a measure of how interesting a compound is to study. It describes how much weight the human evidence can bear — and no more.

5. What the evidence does not establish

Nothing in either literature supports a claim that these peptides treat, cure or prevent any condition, and observational or subgroup signals — including the sepsis subgroup findings and the COVID-19 comparisons — are not therapeutic conclusions. They are prompts for further controlled research. Anyone reading these datasets for research design should treat positive subgroup analyses as hypotheses to be tested prospectively, not as established effects.

6. UK legal status

Both compounds occupy the same position in UK law. Neither holds a UK marketing authorisation, neither is available on NHS prescription, and neither is a controlled drug under the Misuse of Drugs Act 1971 [13,14,15]. Thymalin is registered in the Russian Federation and Tα1 is licensed in a number of countries outside the UK, but neither status has any effect on their UK classification.

The practical consequence is the same as for any research peptide: they may be supplied for laboratory research, but the moment a supplier or clinic makes a medicinal claim for them, the product is a medicine under the Human Medicines Regulations 2012 and the full licensing regime applies. A "research purposes" or "not for human consumption" label does not exempt a product that is being promoted for human use. All content in this library — and this comparison — is framed for research use only.

7. How to read this alongside the profiles

The individual profiles carry the full evidence appraisal, mechanisms, UK status and references for each compound. This comparison exists to make the difference between them legible: two entries that share a family label, a grade and a legal status, but rest on evidence of very different kinds. When two compounds look identical in a catalogue, the useful question is not which is stronger, but which evidence base you would actually be relying on.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.